Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.39 |
| ▸ | PPARG | P37231 | 7/20 | 0.39 |
| ▸ | PPARD | Q03181 | 7/20 | 0.39 |
| ▸ | PPARA | Q07869 | 7/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3670558 | 0.98 | HSD17B10 (0.50) | HSD17B10GMNNTP53POLBMAPT | |
| SCHEMBL11260452 | 0.98 | HSD17B10 (0.50) | HSD17B10GMNNTP53POLBMAPT | |
| SCHEMBL3635726 | 0.93 | — | — | |
| SCHEMBL9299729 | 0.83 | — | — | |
| SCHEMBL1728399 | 0.80 | EPHX1 (0.46) | HSD17B10GMNNTP53POLBMAPT | |
| SCHEMBL5621429 | 0.80 | CES2 (0.50) | HSD17B10GMNNTP53POLBMAPT | |
| SCHEMBL12482041 | 0.80 | CES2 (0.50) | HSD17B10GMNNTP53POLBMAPT | |
| Methyl Alcohol SCHEMBL6886999 | 0.80 | CES2 (0.45) | HSD17B10GMNNTP53POLBMAPT | |
| SCHEMBL9682707 | 0.80 | CES2 (0.50) | HSD17B10GMNNTP53POLBMAPT | |
| SCHEMBL7234137 | 0.80 | CES2 (0.50) | HSD17B10GMNNTP53POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194502-A1 | Protecting Groups for RNA Synthesis | AGILENT TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | claimed |
| CN-1200039-A | Bioconjugates of manganese complexes containing nitrogen macrocyclic ligand, and their application as catalysts of disproportionated super-oxide | MONSANTO CO (US) | 1998-11-25 | — | — | CN | claimed |
| EP-0488248-B1 | Cyan image forming method and silver halide color photographic material containing cyan coupler | FUJI PHOTO FILM CO LTD (JP) | 1997-02-26 | — | — | EP | claimed |
| CN-117580847-A | Macrolide compounds | 范德比尔特大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-111902147-A | Combination cancer therapy of pentaazamacrocycle complexes and platinum-based anticancer agents | 加莱拉实验室有限责任公司 | 2020-11-06 | — | — | CN | disclosed |
| US-8242258-B2 | 2' protected nucleoside monomers protected with orthoester-type and acyl carbonate groups; solid phase synthesis of RNA, oxidation and deprotecting, removal from the support | AGILENT TECHNOLOGIES, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100267702-A1 | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis | HUANG TIEN L | 2010-10-21 | — | — | US | disclosed |
| US-20080194502-A1 | Protecting Groups for RNA Synthesis | AGILENT TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008070831-A2 | BISBENZAMIDINES AND BISBENZAMIDOXIMES FOR THE TREATMENT OF HUMAN AFRICAN TRYPANOSOMIASIS | XAVIER UNIVERSITY OF LOUISIANA (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139534-A1 | or sleeping sickness, caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense; lethargy, continous sleep, breakdown of neurological function, coma and death; viricide, antiprotozoa agent; Pentamidine analog; topoisomerases II inhibitor; inhibit synthesis of DNA, RNA by parasites | XAVIER UNIVERSITY OF LOUISIANA (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1309581-B1 | METHOD FOR THE PREPARATION OF CITALOPRAM | LUNDBECK & CO AS H (DK) | 2004-11-03 | — | — | EP | disclosed |
| EP-1309581-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2003-05-14 | — | — | EP | disclosed |
| EP-1309582-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2003-05-14 | — | — | EP | disclosed |
| US-6509483-B2 | Reacting 5-carboxyphthalide successively with a Grignard reagent of 4-halo-fluorophenyl and a Grignard reagent of 3-halo-N,N-dimethyl-propylamine and then effecting ring closure | H. LUNDBECK A/S (DK) | 2003-01-21 | — | — | US | disclosed |
| US-6426422-B1 | Method for the preparation of citalopram | H. LUNDBECK A/S (DK) | 2002-07-30 | — | — | US | disclosed |
| WO-2002016341-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2002-02-28 | — | — | WO | disclosed |
| US-20020026062-A1 | Method for the preparation of citalopram | H. LUNDBECK A/S (DK) | 2002-02-28 | — | — | US | disclosed |
| US-20020025982-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2002-02-28 | — | — | US | disclosed |
| WO-2002016342-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2002-02-28 | — | — | WO | disclosed |
| CN-1200039-A | Bioconjugates of manganese complexes containing nitrogen macrocyclic ligand, and their application as catalysts of disproportionated super-oxide | MONSANTO CO (US) | 1998-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139534-A1 | or sleeping sickness, caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense; lethargy, continous sleep, breakdown of neurological function, coma and death; viricide, antiprotozoa agent; Pentamidine analog; topoisomerases II inhibitor; inhibit synthesis of DNA, RNA by parasites | TOP2A, TOP2B, TOP1 | HSD17B10 2377/4885GMNN 914/4885TP53 4431/4885 |
| US-20080194502-A1 | Protecting Groups for RNA Synthesis | NSUN2, NSUN3, RNGTT | HSD17B10 1727/4885GMNN 751/4885TP53 4356/4885 |
| US-20020026062-A1 | Method for the preparation of citalopram | HTR3C, HTR4, TPH1 | HSD17B10 746/4885GMNN 648/4885TP53 4802/4885 |
| US-20020025982-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | MAOB, SLC6A4, CYP2D6 | HSD17B10 760/4885GMNN 4515/4885TP53 4514/4885 |
| US-20100267702-A1 | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis | PBRM1, TFB2M, ABAT | HSD17B10 3148/4885GMNN 944/4885TP53 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.